28 results about "Ketoconazole" patented technology

The invention relates to the field of modern pharmacy of traditional Chinese medicines, and discloses application of leonurine in preparation of antibacterial products. According to the invention, the in-vitro antibacterial activity of leonurine is detected by an agar dilution method and a broth trace dilution method. The result shows that the leonurine can inhibit the proliferation of a staphylococcus aureus standard strain, and also has an inhibiting effect on most of methicillin-sensitive staphylococcus aureus, methicillin-resistant staphylococcus aureus and methicillin-resistant coagulase-negative staphylococcus which are obtained by clinical separation; meanwhile, the leonurine can inhibit proliferation of a malassezia standard strain and a clinical isolated strain, also has an inhibiting effect on most of ketoconazole drug-resistant candida and ketoconazole dose dependence-sensitive candida obtained through clinical isolation, and can be used for preparing antibacterial pharmaceutical compositions and skin care products.

The invention provides an application of a fusarium verticillium transcription factor FVEG06682 in regulating the sensitivity of fusarium to azole drugs, and belongs to the technical field of drug resistance. The invention provides an application of a fusarium verticillium transcription factor FVEG06682 in regulating the sensitivity of fusarium to azole drugs or regulating the toxicity of fusarium to plants, and the FVEG06682 improves the sensitivity of fusarium to azole drugs and reduces the toxicity of fusarium to plants through negative regulation. Therefore, the transcription factor is identified and proved to be a key molecule for regulating and controlling the intrinsic resistance of the azole drugs in the fusarium verticillium for the first time, and the sensitivity of pathogenic bacteria to various clinical and agricultural azole drugs (such as ketoconazole, voriconazole, triazolone and tebuconazole) can be remarkably improved by knocking out the FVEG06682 gene; a brand-new and efficient molecular target is provided for overcoming the inherent drug resistance problem of fusarium.

The invention relates to the technical field of medicines, and particularly discloses a polypeptide Loni-P extracted from traditional Chinese medicine honeysuckle, and the amino acid sequence of the polypeptide Loni-P is SEQ ID No.1. The polypeptide can be prepared from honeysuckle through the steps of ultrasonication, enzymolysis, purification and the like. Experiments show that the inhibition rate of Loni-P to malassezia under the concentration of 2 mu g / mL reaches 86 + / -5.29%, which is similar to that of positive control ketoconazole (92 + / -9.17%). The invention further provides a medicated bath component containing Loni-P. The medicated bath component is composed of polypeptide, beta-cyclodextrin, chitosan, fumaric acid, sodium hydroxide and other auxiliary materials and is matched with 200 L of medicated bath water. Clinical experiments show that the medicated bath can remarkably relieve itching, skin lesion area and shape of a chronic eczema patient, and after 30 days of treatment, the score of an experimental group is reduced from 7.93 to 4.0 (a control group has no remarkable change). The polypeptide is natural in source and high in safety, and a new strategy is provided for eczema treatment.

The invention discloses a preparation method for improving the transdermal absorption efficiency of a compound ketoconazole ointment. The preparation method comprises the following steps: step 1, pretreating raw materials; step 2, preparing an oil phase component; step 3, preparing a water-phase component; step 4, construction of a primary emulsification system; step 5, carrying out ultrasonic-assisted secondary emulsification; step 6, carrying out homogenization treatment; step 7, curing at constant temperature; and step 8, quality regulation and packaging. The ketoconazole is subjected to microcapsule embedding treatment by adopting a complex coacervation method, and the composite wall material not only improves the water solubility and dispersion uniformity of the ketoconazole and prevents drugs from aggregating in a matrix to form large particles, but also can protect the drugs from crystal transformation or degradation in the storage process and prolong the validity period of the preparation. The sustained-release effect of the microcapsule can enable the drug to maintain a stable concentration gradient on the skin surface and promote the drug to continuously penetrate through the skin barrier.

The application provides a hybridoma cell strain secreting a monoclone antibody of clotrimazole and application thereof, and relates to the technical field of immune detection. The monoclone antibody secreted by the hybridoma cell strain has good sensitivity and specificity to clotrimazole, wherein the IC 50 value of clotrimazole is 7.386 ng / mL, and the monoclone antibody has good sensitivity; and the monoclone antibody has no cross reaction to functional analogues of clotrimazole, such as miconazole, econazole, ketoconazole, bifonazole and sertaconazole, and has good specificity. Therefore, the monoclone antibody of clotrimazole secreted by the hybridoma cell strain can accurately detect low-concentration clotrimazole.

The present application relates to the technical field of microorganism, and particularly relates to a streptococcus lactis with a cat dandruff treatment function and application thereof. Pediococcus acidilactici The streptococcus lactis is preserved in the Guangdong Provincial Microbial Culture Collection Center on September 26, 2025, and the preservation number is GDMCC No: 67035. The streptococcus lactis and the inactivated bacteria solution provided in the present application have good inhibitory effects on trichophyton mentagrophytes and mycosporum gypseum. The streptococcus lactis provided in the present application can also be used for treating cat dandruff, and compared with ketoconazole cream, the streptococcus lactis has faster effect and shorter treatment cycle.

The application discloses an antifungal azole derivative, a synthesis method and application thereof, and has a general formula shown in formula (I). The azole derivative is synthesized by recombination of fluconazole and ketoconazole structural units, and the application of the azole derivative provided by the application is the application in preparation of antifungal drugs. The azole derivative synthesized by the application is superior to fluconazole (FLC) in inhibiting effect on Candida albicans, and the MIC 50 value can be as low as 0.0218 μg / mL, thereby providing a new direction for research and preparation of an antifungal drug for Candida albicans.

The invention provides a preparation method of compound ketoconazole cream, and relates to the technical field of external ointment. The ketoconazole emulsifiable paste comprises the following components in percentage by mass: 0.1-2% of ketoconazole, 2-5% of camphor oil and 10-15% of a traditional Chinese medicine extract, and 20-30% of a compound emulsifier. The components comprise, by weight, 10-20% of a humectant, 0.1-0.2% of a preservative, 0.1-0.3% of an antioxidant, and the balance of water; the traditional Chinese medicine extract is a mixed alcohol extract of wormwood, dandelion and mint; the compound emulsifier is formed by mixing hexadecyl trimethyl ammonium bromide and lauryl sodium sulfate. The compound ketoconazole emulsifiable paste prepared by the invention does not contain glucocorticoid, and through the synergistic effect of the Chinese herbal medicine extract, ketoconazole and camphor oil, the drug effect can be remarkably improved, so that the radical treatment of diseases is realized. The compound ketoconazole cream disclosed by the invention does not irritate skin and has no side reaction.

The invention discloses a rodent sterilant synergist and application of the rodent sterilant synergist in preparation of sterilant bait. According to the invention, ketoconazole with relatively strong CYP enzyme inhibitory activity is taken as a synergist and is compounded with mifepristone and baits to form the compound sterilant for harmful rats. Wherein ketoconazole can effectively inhibit the activity of CYP enzyme, significantly reduce the metabolic clearance rate of mifepristone, improve the oral bioavailability of mifepristone, maintain the same sterility prevention and control effect, greatly reduce the use dosage of the sterilant, and realize reduction and synergy. The compound pest sterilant provided by the invention solves the problems of poor killing effect, short lasting effect, fast rebound, high cost, easy generation of drug resistance and accidental killing of natural enemies and non-target organisms in the existing single use of a steroid hormone sterilant, and provides a new solution for sustainable control of pest.

The invention relates to a hybridoma cell strain secreting an isavuconazole monoclonal antibody and application of the hybridoma cell strain, and belongs to the technical field of immunodetection. The monoclonal antibody secreted by the hybridoma cell strain has good sensitivity and specificity to the isavuconazole, the IC50 value of the monoclonal antibody to the isavuconazole is 13.317 ng / mL, and the IC50 value of the monoclonal antibody to the structural analogue of the isavuconazole is 13.317 ng / mL. According to the present invention, the low-concentration isavuconazole, such as fluconazole, ketoconazole, posaconazole, clotrimazole, miconazole, econazole, voriconazole, bifenconazole, luliconazole and sertaconazole, does not have the cross reaction, and the cross reaction rate is less than 1%, such that the low-concentration isavuconazole can be accurately detected.

The invention belongs to the technical field of microneedles, and discloses a co-amorphous microneedle for treating alopecia and a preparation method thereof. According to the invention, ketoconazole and polylipoic acid are prepared into a [ketoconazole] [polylipoic acid] co-amorphous compound, and the co-amorphous microneedle which takes the co-amorphous compound as a needle tip and takes hyaluronic acid and glucan as bases is further prepared. The skin permeability of ketoconazole is enhanced through microneedle administration, and release and permeation of ketoconazole are accelerated through in-situ melting after administration, so that the external bioavailability of ketoconazole is improved, and the prepared co-amorphous microneedle has a good synergistic effect on external delivery of ketoconazole and treatment of alopecia.

Compositions and methods for the treatment of onychomycosis. The compositions include a pharmaceutically effective amount of one or more anti-fungal agents in a petrolatum carrier. The one or more anti-fungal agents may include, for example, terbinafine HCl, ciclopirox, ciclopirox olamine, fluconazole, itraconazole, ketoconazole, amorolfine, efinaconazole, clotrimazole, miconazole (miconazole nitrate), and any combination thereof.

The invention discloses a formula and application of a compound infertility agent containing ketoconazole and quinestrol and based on CYP enzyme activity inhibition. Ketoconazole, quinestrol and specific baits are compounded to form the reduction and synergism type compound rodent pest sterilant, ketoconazole can effectively inhibit CYP enzyme activity, obviously reduce the metabolic clearance rate of quinestrol and improve the oral bioavailability of quinestrol, and the use dosage of the sterilant is greatly reduced while the same sterility prevention and control effect is maintained. The compound pest sterilant provided by the invention solves the common problems of poor killing effect, short lasting period, fast rebound, high cost, easy generation of drug resistance, accidental killing of natural enemies and non-target organisms and the like existing in the existing single use of steroid hormone sterilant, and provides a new solution way for sustainable control of pest.

A process for the preparation of Levoketoconazole (1) includes reacting ketoconazole with (1S)-(+) camphor sulphonic acid in a solvent to give (1S)-(+) camphor sulphonic acid salt of Levoketoconazole; treating Levoketoconazole Camphor sulphonic acid with an aqueous base to give crude Levoketoconazole (1); and isolating and purifying crude Levoketoconazole (1) to yield pure Levoketoconazole (1). A process for the preparation of crystalline anhydrous Levoketoconazole (1) is also included.

The invention belongs to the technical field of hand and foot nursing, and discloses a non-corrosive body surface cutin hyperplasia nursing patch as well as a preparation method and application thereof. The nursing patch is sequentially provided with a three-layer basic structure including a bacteriostatic functional layer, a flexible substrate and a breathable protective layer from the skin contact side to the outer side, the bacteriostatic functional layer is compounded by clotrimazole, bifonazole and ketoconazole, and the mass ratio of clotrimazole to bifonazole to ketoconazole is (1-2): (1.5-2.5): (0.6-1.5). According to the non-corrosive body surface cutin hyperplasia nursing patch, the root of cutin abnormal hyperplasia is cut off through the antibacterial components, meanwhile, cutin is mildly softened and ablated, and normal skin barriers are not damaged.

1. The name of the design product: packaging box (compound ketoconazole hair lotion). 2. The use of the design product: for product outer packaging. 3. The design points of the design product: in the combination of shape and pattern. 4. The picture or photo that best indicates the design points: unfolded state reference drawing.

The invention belongs to the technical field of biological medicines, and particularly discloses a polypeptide with malassezia resisting activity and application of the polypeptide in improvement of seborrheic dermatitis. The polypeptide provided by the invention comprises an amino acid sequence as shown in SEQ ID NO: 1. The polypeptide has a remarkable inhibiting effect on the key pathogenic bacterium-malassezia causing seborrheic dermatitis, experimental data shows that the polypeptide can remarkably inhibit the growth and constant value of the malassezia at a low concentration, and the effect of the polypeptide can be close to that of a positive control ketoconazole. The polypeptide shows an excellent dermatophyte removing effect in a malassezia induced mouse seborrheic dermatitis model, experimental data proves that the fungal load of the skin tissue of the affected part of a mouse is remarkably reduced after administration, and the polypeptide still can keep high biological activity and stability in a complex skin physiological microenvironment, and has a good application prospect. The malassezia can effectively penetrate through a sebum layer to act on thalli, so that the decomposition effect of the malassezia on sebum is effectively restrained.

The application belongs to the technical field of drug use, and particularly relates to an application of febuxostat in preparation of an antifungal drug and an antifungal composition. The application expands the application range and indications of febuxostat, improves the selection range of the antifungal drug, improves the antifungal effect, and has an inhibiting effect on a ketoconazole-resistant strain.

The present invention relates to a ketoconazole suppository, a preparation method therefor, and a quality control method therefor. The ketoconazole suppository exhibits a dissolution rate of any one or two or more of the following: (1) the cumulative dissolution percentage of ketoconazole measured at pH 4.0-5.5 for 30 minutes is ≥ 15%; (2) the cumulative dissolution percentage of ketoconazole measured at pH 4.0-5.5 for 1 hour is ≥ 30%; (3) the cumulative dissolution percentage of ketoconazole measured at pH 4.0 for 30 minutes is ≥ 40%; and (4) the cumulative dissolution percentage of ketoconazole measured at pH 4.0 for 1 hour is ≥ 60%.

The invention discloses ketoconazole emulsifiable paste and a preparation method thereof, and the ketoconazole emulsifiable paste is prepared from the following components in parts by weight: 1 to 25 parts of ketoconazole, 1 to 80 parts of stearic acid, 1 to 55 parts of glyceryl monostearate and glyceryl distearate, 1 to 130 parts of light liquid paraffin, 0.1 to 1 part of ethylparaben, 100 to 350 parts of glycerol, 0.1 to 2 parts of edetate disodium, 1 to 6 parts of triethanolamine and 1 to 5 parts of anhydrous sodium sulfite. 0.1 to 2 parts of butylated hydroxytoluene, and 100 to 450 parts of purified water. The stability, the drug effect and the safety are comprehensively improved, the bacteriostasis effect on candida albicans is obvious, the treatment efficiency is improved, and the better fungal infection resisting effect is achieved.

The invention relates to the technical field of microorganisms, in particular to pediococcus acidilactici with a cat tinea treatment function and application of the pediococcus acidilactici. The pediococcus acidilactici disclosed by the invention is preserved in the Guangdong Microbial Culture Collection Center on September 26, 2025, and the preservation number is GDMCC No: 67035. The pediococcus acidilactici disclosed by the invention has the advantages that the pediococcus acidilactici is preserved in the Guangdong Microbial Culture Collection Center on September 26, 2025; the pediococcus acidilactici and the inactivated bacterial liquid thereof, provided by the invention, have a good inhibition effect on trichophyton mentagrophytes and microsporum gypsum. The pediococcus acidilactici provided by the invention can also be used for treating tinea of cats, and compared with ketoconazole cream, the pediococcus acidilactici has the advantages of quicker effect and shorter treatment cycle.

The application discloses a preparation method of a ketoconazole metabolite. The ketoconazole metabolite is an aromatic ring oxide of ketoconazole, and no synthesis report is found at present. In-vitro synthesis of the drug has extremely important research significance for studying the metabolism of ketoconazole. The preparation method has reasonable process design and simple experiment operation, and lays a foundation for future industrial production. The prepared ketoconazole metabolite has high purity, and provides important scientific support for the research of the ketoconazole metabolite.

Provided herein is a method of administering levoketoconazole, or a pharmaceutically acceptable salt thereof, to a subject in need thereof, wherein the subject is also being administered a multidrug and toxin extrusion transporter 1 (MATE1) substrate or an organic cation transporter 2 (OCT2) substrate.

The invention relates to a hybridoma cell strain secreting an isavuconazole monoclonal antibody and application of the hybridoma cell strain, and belongs to the technical field of immunodetection. The monoclonal antibody secreted by the hybridoma cell strain has good sensitivity and specificity to the isavuconazole, the IC50 value of the monoclonal antibody to the isavuconazole is 13.317 ng / mL, and the IC50 value of the monoclonal antibody to the structural analogue of the isavuconazole is 13.317 ng / mL. According to the present invention, the low-concentration isavuconazole, such as fluconazole, ketoconazole, posaconazole, clotrimazole, miconazole, econazole, voriconazole, bifenconazole, luliconazole and sertaconazole, does not have the cross reaction, and the cross reaction rate is less than 1%, such that the low-concentration isavuconazole can be accurately detected.

The invention relates to a preparation method of a hydrophobic natural-drug-effect micromolecule self-assembled hydrogel sustained-release drug delivery system and wound repair application. Belongs to the technical field of biological materials and pharmaceutical preparations. The hydrogel has antibacterial, anti-inflammatory and wound repairing capabilities, can selectively inhibit drug-resistant bacteria and fungi, and does not influence the activity of probiotics; the entrapment performance on exosomes and various pharmacodynamic molecules is good. Wherein the coptisine and chrysin self-assembled hydrogel is uniform and stable in form, has dual antibacterial activity superior to those of penicillin G, ketoconazole and the like, and has a value of being developed into a carrier-free supramolecular nano-drug. In the preparation process, compared with the traditional technology, the method is simpler and more environmentally friendly, high in repeatability and has industrial production potential. In application, the sustained-release delivery system can remarkably shorten the wound healing period and reduce the infection risk, and shows good applicability and treatment effect on complex wounds such as acute skin wounds, chronic ulcers and diabetic feet.

The utility model relates to the field of medicine product emulsification, in particular to a ketoconazole cream emulsifying device which comprises a base, a fixing ring, a heating tank, a top plate, an assembly frame, a first motor, a second bevel gear, a third bevel gear, a stirring paddle and the like, two supporting rods are arranged on the upper portion of the machine base, a fixing ring is rotationally arranged between the two supporting rods of the machine base, a heating tank is arranged on the inner side of the fixing ring, a top plate is arranged on the top of the heating tank, an assembling frame is arranged on the rear side of the top of the top plate, and a first motor is arranged on the top of the assembling frame. A second bevel gear is rotationally arranged in the middle of the top of the top plate, a third bevel gear is arranged on an output shaft of the first motor, and a stirring paddle is arranged at the bottom of the third bevel gear. By adjusting the angle of the efficient stirring system and the heating tank, uniform mixing of oil-phase and water-phase components is ensured; due to the design of the foam scraping frame and the filter screen, foams and impurities are effectively removed, the purity of the cream is improved, and the requirement for manual intervention is reduced.

The invention provides a trypsin inhibitor and application thereof, and relates to the technical field of molecular biology. According to the invention, it is found for the first time that zinc pyrithione, ketoconazole and / or selenium disulfide have an inhibition effect on trypsin activity, and new functional components which are convenient to obtain are provided for the trypsin inhibitor. The invention provides three compositions containing zinc hyaluronate, the zinc hyaluronate is respectively compounded with zinc pyrithione, ketoconazole or selenium disulfide according to a specific mass ratio, and it is found for the first time that the zinc hyaluronate and the zinc pyrithione, ketoconazole or selenium disulfide show the activity of synergistically inhibiting trypsin. The composition provided by the invention is simple to obtain, can be continuously compounded with other functional active components or auxiliary material components to obtain commercial products, and has a wide application prospect.